|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.600 USD | -1.13% |
|
-.--% | - |
| 25-05-22 | OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P Global BMI Index | CI |
| 25-05-22 | OptiNose, Inc.(NasdaqGS:OPTN) dropped from S&P TMI Index | CI |
| Market Cap | 97.22M 84.42M 78.71M 72.31M 137M 9.25B 138M 928M 363M 4.62B 365M 357M 15.32B | P/E 2023 |
-4.07x | P/E 2024 | -3.15x |
|---|---|---|---|---|---|
| Enterprise Value | 142M 123M 115M 105M 199M 13.48B 201M 1.35B 529M 6.74B 532M 520M 22.33B | EV / Sales 2023 |
2.86x | EV / Sales 2024 | 1.43x |
| Free-Float |
6.21% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -1.13% |
| 3 years | 4.81 |  | 31.5 |
| 5 years | 4.81 | | 64.5 |
| 10 years | 4.81 | | 450 |
| Manager | Title | Age | Since |
|---|---|---|---|
Evan Loh
CEO | Chief Executive Officer | 67 | 2025-05-20 |
| Chief Tech/Sci/R&D Officer | - | 2019-12-31 | |
Jonathan Neely
IRC | Investor Relations Contact | - | 2020-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Evan Loh
BRD | Director/Board Member | 67 | 2025-05-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 5/21/25 | Issuer sale | Chief Financial Officer | 82,491 | 0.8204% | ||
| 5/21/25 | Issuer sale | Director | 12,624 | 0.1255% | ||
| 5/21/25 | Issuer sale | Director | 12,624 | 0.1255% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -.--% | -.--% | -49.61% | 97.22M | |
| +4.34% | -3.82% | +51.95% | +156.31% | 995B | |
| +0.98% | -3.17% | +50.58% | +48.53% | 614B | |
| +2.04% | -5.61% | +25.18% | +65.33% | 431B | |
| +1.75% | +0.53% | +42.36% | +37.29% | 353B | |
| +0.55% | -3.55% | +31.08% | +39.28% | 293B | |
| +3.20% | -8.12% | +7.56% | +10.86% | 245B | |
| +6.50% | +6.68% | +37.81% | +63.49% | 210B | |
| -3.97% | -12.84% | -3.68% | -46.01% | 210B | |
| -2.50% | -0.24% | +17.74% | +64.14% | 168B | |
| Average | +1.15% | -4.52% | +26.06% | +38.96% | 351.83B | |
| Weighted average by Cap. | +2.10% | -5.89% | +36.85% | +72.55% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 70.99M 61.64M 57.47M 52.79M 99.85M 6.75B 101M 678M 265M 3.38B 267M 261M 11.18B | 78.23M 67.92M 63.33M 58.18M 110M 7.44B 111M 747M 292M 3.72B 294M 287M 12.32B |
| Net income | -35.48M -30.81M -28.73M -26.39M -49.91M -3.38B -50.46M -339M -132M -1.69B -133M -130M -5.59B | -21.54M -18.7M -17.44M -16.02M -30.3M -2.05B -30.63M -206M -80.37M -1.02B -80.89M -79.12M -3.39B |
| Net Debt | 58.06M 50.42M 47.01M 43.18M 81.67M 5.52B 82.57M 554M 217M 2.76B 218M 213M 9.15B | 44.48M 38.62M 36.01M 33.08M 62.56M 4.23B 63.24M 425M 166M 2.11B 167M 163M 7.01B |
Employees
128
Sector
Pharmaceuticals
- Stock Market
- Stocks
- OPTN Stock
Select your edition
All financial news and data tailored to specific country editions
